135 related articles for article (PubMed ID: 4015071)
41. Metabolism of 2-amino-3-methylimidazo[4,5-f]quinoline in the male rat.
Inamasu T; Luks H; Vavrek MT; Weisburger JH
Food Chem Toxicol; 1989 Jun; 27(6):369-76. PubMed ID: 2792966
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics, tissue distribution, and excretion of sitafloxacin, a new fluoroquinolone antibiotic, in rats, dogs, and monkeys.
Tachibana M; Tanaka M; Mitsugi K; Jin Y; Takaichi M; Okazaki O
Arzneimittelforschung; 2004; 54(12):898-905. PubMed ID: 15646375
[TBL] [Abstract][Full Text] [Related]
43. Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways.
Dalvie DK; Khosla NB; Navetta KA; Brighty KE
Drug Metab Dispos; 1996 Nov; 24(11):1231-40. PubMed ID: 8937858
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats.
Okuyama Y; Momota K; Morino A
Arzneimittelforschung; 1997 Mar; 47(3):285-92. PubMed ID: 9105547
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of prulifloxacin. 3rd communication: metabolism in rats, dogs and monkeys.
Okuyama Y; Morino A
Arzneimittelforschung; 1997 Mar; 47(3):293-8. PubMed ID: 9105548
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys.
Nonaka K; Tsujioka T; Tougou K; Mukai H
Arzneimittelforschung; 2003; 53(9):612-20. PubMed ID: 14558434
[TBL] [Abstract][Full Text] [Related]
47. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
48. Disposition and metabolism of [14C]sparfloxacin after repeated administration in the rat.
Matsunaga Y; Miyazaki H; Nomura N; Hashimoto M
Arzneimittelforschung; 1991 Jul; 41(7):760-3. PubMed ID: 1663355
[TBL] [Abstract][Full Text] [Related]
49. Inhibitory and bactericidal activities of amifloxacin, a new quinolone carboxylic acid, compared with those of seven other antimicrobial agents.
Baltch AL; Sutphen NT; Smith RP; Conley PE
Clin Ther; 1984; 7(1):73-80. PubMed ID: 6440708
[TBL] [Abstract][Full Text] [Related]
50. Disposition and metabolism of [14C]-haloperidol in rats.
Miyazaki H; Matsunaga Y; Nambu K; Oh-e Y; Yoshida K; Hashimoto M
Arzneimittelforschung; 1986 Mar; 36(3):443-52. PubMed ID: 3707663
[TBL] [Abstract][Full Text] [Related]
51. Disposition of moxalactam and N-methyltetrazolethiol in rats and monkeys.
Mizojiri K; Norikura R; Takashima A; Tanaka H; Yoshimori T; Inazawa K; Yukawa T; Okabe H; Sugeno K
Antimicrob Agents Chemother; 1987 Aug; 31(8):1169-76. PubMed ID: 3631941
[TBL] [Abstract][Full Text] [Related]
52. The disposition of a novel tetrahydroquinoline, tiquinamide, in rats and patas monkeys.
Pierce DM; Body CE; Franklin RA
Eur J Drug Metab Pharmacokinet; 1982; 7(3):173-82. PubMed ID: 7173271
[TBL] [Abstract][Full Text] [Related]
53. [Absorption, distribution, excretion and metabolism of [14C] T-3761 in rats and mice].
Hayakawa H; Hayashi K; Sakai H; Ishikura H; Takagi H; Nakajima Y; Sogame Y
Jpn J Antibiot; 1995 May; 48(5):671-85. PubMed ID: 7637202
[TBL] [Abstract][Full Text] [Related]
54. Metabolic disposition of Rolziracetam in laboratory animals.
Black A; Chang T
Eur J Drug Metab Pharmacokinet; 1987; 12(2):135-43. PubMed ID: 3691579
[TBL] [Abstract][Full Text] [Related]
55. Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group.
Boyko EJ; Iravani A; Silverman MH; Schelling DJ; Wright RA
Antimicrob Agents Chemother; 1990 Apr; 34(4):665-7. PubMed ID: 2188590
[TBL] [Abstract][Full Text] [Related]
56. Metabolism and disposition of sulfinalol in laboratory animals.
Benziger DP; Fritz A; Edelson J
Drug Metab Dispos; 1981; 9(6):493-8. PubMed ID: 6120804
[TBL] [Abstract][Full Text] [Related]
57. Reversed-phase ion-pair high-performance liquid chromatographic determination of fluoroquinolones in human plasma.
Nangia A; Lam F; Hung CT
J Pharm Sci; 1990 Nov; 79(11):988-91. PubMed ID: 2292775
[TBL] [Abstract][Full Text] [Related]
58. Absorption, disposition kinetics, and metabolic pathways of cyclohexene oxide in the male Fischer 344 rat and female B6C3F1 mouse.
Sauer JM; Bao J; Smith RL; McClure TD; Mayersohn M; Pillai U; Cunningham ML; Sipes IG
Drug Metab Dispos; 1997 Mar; 25(3):371-8. PubMed ID: 9172957
[TBL] [Abstract][Full Text] [Related]
59. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
60. Metabolism and disposition of erythritol after oral administration to rats.
Noda K; Oku T
J Nutr; 1992 Jun; 122(6):1266-72. PubMed ID: 1588443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
